Publication | Closed Access
Adenosine A <sub>2A</sub> receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)
346
Citations
18
References
2008
Year
Istradefylline was safe, well tolerated, and offered a clinically meaningful reduction in "off" time without increased troublesome dyskinesia.
| Year | Citations | |
|---|---|---|
Page 1
Page 1